Press releaseGlobe Newswire
Acrivon Therapeutics
ACRV · NASDAQ
$1.80+$0.105 (+6.21%)TodayMarket closed ·
Prev close $1.69
Latest news
- Press releaseGlobe Newswire
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
- Press releaseGlobe Newswire
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
- Press releaseGlobe Newswire
Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
- Press releaseGlobe Newswire
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
- Press releaseGlobe Newswire
Registration Momentum Builds Across the Oncology Pipeline
- Press releasePRNewswire
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
- NewsAvi Kapoor
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings
- News
Market-Moving News for January 8th
- Press releaseGlobe Newswire
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
- Press releaseGlobe Newswire
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
- Press releaseGlobe Newswire
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
- Press releaseGlobe Newswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
- Press releaseGlobe Newswire
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
- Press releaseGlobe Newswire
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.